ezetimibe has been researched along with 1-anilino-8-naphthalenesulfonate in 7 studies
| Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) | Studies (1-anilino-8-naphthalenesulfonate) | Trials (1-anilino-8-naphthalenesulfonate) | Recent Studies (post-2010) (1-anilino-8-naphthalenesulfonate) |
|---|---|---|---|---|---|
| 2,484 | 563 | 1,465 | 24,275 | 480 | 7,815 |
| Protein | Taxonomy | ezetimibe (IC50) | 1-anilino-8-naphthalenesulfonate (IC50) |
|---|---|---|---|
| Chain A, RNA-directed RNA polymerase NS5 | Dengue virus 2 16681-PDK53 | 100 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 1.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmad, I; Hotiana, M; Hussain, M; Rahman, F; Ruby, E; Usman, H | 1 |
| Berthold, HK; Giannakidou, E; Gouni-Berthold, I; Gylling, H; Hallikainen, M; Ko, Y; Krone, W; Mantzoros, CS; Patel, D; Plat, J; Seedorf, U; Soutar, AK; Stier, S | 1 |
| Rosenson, RS | 1 |
| Inazu, A; Kawashiri, MA; Kobayashi, J; Mabuchi, H; Miyashita, K; Nakajima, K; Nohara, A; Tada, H; Yamagishi, M | 1 |
| Agrawal, S; Fornoni, A; Smoyer, WE; Zaritsky, JJ | 1 |
| Song, Z; Wang, X; Xing, D; Xue, J; Zhang, R | 1 |
| Chen, P; Jia, A; Jiang, H; Liu, W; Sun, J; Xu, Q; Zhang, R | 1 |
1 review(s) available for ezetimibe and 1-anilino-8-naphthalenesulfonate
| Article | Year |
|---|---|
Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, VLDL; Dyslipidemias; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipase; Lipoprotein Lipase; Lipoproteins; Nephrotic Syndrome; Niacin; Proprotein Convertase 9; Triglycerides | 2018 |
2 trial(s) available for ezetimibe and 1-anilino-8-naphthalenesulfonate
| Article | Year |
|---|---|
Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Gene Expression Regulation, Enzymologic; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Lipase; Male; Membrane Proteins; Membrane Transport Proteins; Proprotein Convertase 9; Proprotein Convertases; Prospective Studies; Receptors, LDL; Serine Endopeptidases; Simvastatin | 2008 |
Changes in lipoprotein lipase and endothelial lipase mass in familial hypercholesterolemia during three-drug lipid-lowering combination therapy.
Topics: Adult; Aged; Anticholesteremic Agents; Drug Therapy, Combination; Epichlorohydrin; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Imidazoles; Lipase; Lipoprotein Lipase; Male; Middle Aged; Receptors, LDL; Resins, Synthetic; Rosuvastatin Calcium | 2016 |
4 other study(ies) available for ezetimibe and 1-anilino-8-naphthalenesulfonate
| Article | Year |
|---|---|
Ezetimibe-induced acute pancreatitis.
Topics: Anticholesteremic Agents; Azetidines; Diagnosis, Differential; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Lipase; Middle Aged; Pancreatitis, Acute Necrotizing | 2007 |
Functional assessment of HDL: Moving beyond static measures for risk assessment.
Topics: Amides; Animals; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Esters; Ezetimibe; Glucose; Humans; Insulin; Lipase; Lipoproteins, HDL; Niacin; Quinolines; Risk Assessment; Risk Factors; Sulfhydryl Compounds | 2010 |
One-step modification to identify dual-inhibitors targeting both pancreatic triglyceride lipase and Niemann-Pick C1-like 1.
Topics: Anticholesteremic Agents; Binding Sites; Cell Line, Tumor; Drug Design; Ezetimibe; Gene Expression Regulation; Humans; Hypercholesterolemia; Lipase; Membrane Transport Proteins; Molecular Docking Simulation; Molecular Dynamics Simulation; Orlistat; Pancreas | 2021 |
Novel application potential of cinaciguat in the treatment of mixed hyperlipidemia through targeting PTL/NPC1L1 and alleviating intestinal microbiota dysbiosis and metabolic disorders.
Topics: Cholesterol; Dysbiosis; Ezetimibe; Gastrointestinal Microbiome; Humans; Hyperlipidemias; Lipase; Lipidoses; Membrane Transport Proteins; Triglycerides | 2023 |